Since we previously reported that ODN-mediated Raptor downregulation enhances sensitivity to anti-cancer drugs [12], we examined the involvement of SHP2 activation in apoptosis induced by combination treatment (ODN plus oxaliplatin). Here, RPTOR is linked to cancer.